RxDoctor Payments DataLook up a doctor →

Ramtin Agah, MD

Cardiology · Mountain View, CANPI 1255326310

Payments from drug & device makers

$360,826in general payments, 2019–2025

Across 460 payments — averaging $784.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$357K
  • Novartis$515
  • Novo Nordisk$471
  • Esperion Therapeutics, Inc.$305
  • Amgen$298
  • Pfizer$250
  • plus $2K from 18 others
$26,925in research payments, 2019–2025

Across 28 payments — averaging $961.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$27K

What the payments were for

  • Consulting fees$356,77599%
  • Food & beverage$3,8871%
  • Education$1640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$360,826 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$293,372
Medicare patients
802
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$282,923
OzempicSemaglutide157$195,178
XareltoRivaroxaban89$125,121
EntrestoSacubitril/Valsartan60$94,232
FarxigaDapagliflozin Propanediol55$71,678
MounjaroTirzepatide51$56,765
JardianceEmpagliflozin32$44,742
Repatha SureclickEvolocumab40$34,635
Praluent PenAlirocumab12$9,638
Rosuvastatin Calcium498$9,444
Nebivolol Hcl65$5,356
Metoprolol Succinate179$2,923
Flecainide Acetate64$2,873
Valsartan70$2,813
Amiodarone Hcl58$2,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$250$282,923214 claims
Novo NordiskOzempic$471$195,178157 claims
Johnson & JohnsonXarelto$180$125,12189 claims
NovartisEntresto$515$94,23260 claims
AstraZenecaFarxiga$206$71,67855 claims
Boehringer IngelheimJardiance$25$44,74232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 cardiology providers in California.

Other cardiology in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →